NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.05 +0.20 (+1.84 %)
(As of 06/17/2018 04:00 PM ET)
Previous Close$11.05
Today's Range$10.75 - $11.10
52-Week Range$9.85 - $29.00
Volume624,796 shs
Average Volume474,354 shs
Market Capitalization$349.14 million
P/E Ratio-3.35
Dividend YieldN/A
Beta0.55

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone617-807-6600

Debt

Debt-to-Equity Ratio0.47
Current Ratio8.06
Quick Ratio8.06

Price-To-Earnings

Trailing P/E Ratio-3.35
Forward P/E Ratio-3.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.62 million
Price / Sales27.67
Cash FlowN/A
Price / CashN/A
Book Value$2.65 per share
Price / Book4.17

Profitability

EPS (Most Recent Fiscal Year)($3.30)
Net Income$-89,060,000.00
Net Margins-707.08%
Return on Equity-87.29%
Return on Assets-50.20%

Miscellaneous

Employees83
Outstanding Shares31,600,000

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) posted its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.94) by $0.03. The specialty pharmaceutical company earned $0.01 million during the quarter, compared to the consensus estimate of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. View Paratek Pharmaceuticals' Earnings History.

What price target have analysts set for PRTK?

7 brokers have issued 1 year price targets for Paratek Pharmaceuticals' stock. Their forecasts range from $36.00 to $55.00. On average, they expect Paratek Pharmaceuticals' share price to reach $45.00 in the next year. View Analyst Ratings for Paratek Pharmaceuticals.

Who are some of Paratek Pharmaceuticals' key competitors?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 60)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
  • Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 51)

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Media coverage about PRTK stock has been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a news sentiment score of 0.10 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 46.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Highland Capital Management LP (3.04%), C WorldWide Group Holding A S (1.58%), Northern Trust Corp (1.14%), Water Island Capital LLC (0.81%) and JPMorgan Chase & Co. (0.72%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Michael Bigham and Robert S Radie. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S, Prosight Management LP, JPMorgan Chase & Co. and Opus Point Partners Management LLC. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham and Robert S Radie. View Insider Buying and Selling for Paratek Pharmaceuticals.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was purchased by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Omni Partners LLP, BlackRock Inc., California Public Employees Retirement System, Water Island Capital LLC, A.R.T. Advisors LLC, Trellus Management Company LLC and Northern Trust Corp. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $11.05.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $349.14 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]


MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  484
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.